{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T06:53:59Z","timestamp":1793084039644,"version":"4.5.0"},"reference-count":15,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["TL1TR001883"],"award-info":[{"award-number":["TL1TR001883"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["ACR Open Rheumatology"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Glucagon\u2010like peptide 1 receptor agonists (GLP\u20101RAs) are approved for weight loss, diabetes, and cardiovascular risk reduction. Despite widespread use, GLP\u20101RAs have not been well studied in patients with rheumatoid arthritis (RA). We examined the effects of GLP\u20101RAs on RA disease activity and cardiovascular risk profile in patients with RA and overweight or obesity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective chart review study of patients with RA with a body mass index of \u226527 who were prescribed a GLP\u20101RA (semaglutide or tirzepatide). Between 2018 and 2024, 173 patients with RA were identified in the treatment group (prescribed and took a GLP\u20101RA), and 42 patients with RA were identified in the control group (prescribed but did not take GLP\u20101RA). Patients were assessed at three\u2010month intervals for up to one year after prescription. Outcome measures included RA disease activity, cardiovascular risk markers, and patient\u2010reported outcomes. Changes in outcome measures within and between groups were assessed with linear mixed effect models, with adjustments for baseline characteristics that differed significantly between groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      GLP\u20101RA\u2013treated patients experienced significantly greater reductions in RA disease activity, pain, body weight, total cholesterol, and glycosylated hemoglobin than controls (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.05). Within the treatment group, there were also significant reductions in erythrocyte sedimentation rate, C\u2010reactive protein values, low\u2010density lipoprotein cholesterol values, and triglyceride values (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.05). Nearly one\u2010third of the treatment group discontinued the GLP\u20101RA during the study period, with the most common adverse effect being gastrointestinal issues.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study suggests that the use of GLP\u20101RAs can improve RA disease activity and cardiovascular risk profile. Although further research is needed, this novel finding has significant clinical implications because it suggests that anti\u2010obesity medications may improve both cardiovascular and RA outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/acr2.70103","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T11:04:18Z","timestamp":1757588658000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Effect of Glucagon\u2010Like Peptide 1 Receptor Agonists on Patients With Rheumatoid Arthritis"],"prefix":"10.1002","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6510-364X","authenticated-orcid":false,"given":"David A.","family":"Kellner","sequence":"first","affiliation":[{"name":"David Geffen School of Medicine University of California  Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Dente","sequence":"additional","affiliation":[{"name":"David Geffen School of Medicine University of California  Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Tran","sequence":"additional","affiliation":[{"name":"David Geffen School of Medicine University of California  Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis","family":"Welsh","sequence":"additional","affiliation":[{"name":"David Geffen School of Medicine University of California  Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Tran","sequence":"additional","affiliation":[{"name":"David Geffen School of Medicine University of California  Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angshuman","family":"Saha","sequence":"additional","affiliation":[{"name":"David Geffen School of Medicine University of California  Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua F.","family":"Baker","sequence":"additional","affiliation":[{"name":"Perelman School of Medicine, University of Pennsylvania and Corporal Michael J. Crescenz Veterans Affairs Medical Center  Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Elashoff","sequence":"additional","affiliation":[{"name":"David Geffen School of Medicine University of California  Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3417-9478","authenticated-orcid":false,"given":"Veena K.","family":"Ranganath","sequence":"additional","affiliation":[{"name":"David Geffen School of Medicine University of California  Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,9,11]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22932"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-015-3154-0"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.30291"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.142133"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206411"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39098"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22629"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac307"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2019.105732"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.4703-13.2014"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403664"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2021.4182"}],"container-title":["ACR Open Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr2.70103","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T08:17:48Z","timestamp":1759479468000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr2.70103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1002\/acr2.70103"],"URL":"https:\/\/doi.org\/10.1002\/acr2.70103","archive":["Portico"],"relation":{},"ISSN":["2578-5745","2578-5745"],"issn-type":[{"value":"2578-5745","type":"print"},{"value":"2578-5745","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"2025-05-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70103"}}